Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | EDNRB | P24530 | 3/20 | 0.36 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.35 |
| ▸ | EED | O75530 | 3/20 | 0.35 |
| ▸ | SUZ12 | Q15022 | 2/20 | 0.35 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.35 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GNRHR | P30968 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832321 | 0.94 | F2RL3 (0.42) | KMT2AMEN1CYP2C19EDNRBF2RL3 | |
| SCHEMBL832410 | 0.90 | EDNRB (0.44) | KMT2AMEN1PPARGEDNRBF2RL3 | |
| SCHEMBL829986 | 0.87 | KMT2A (0.39) | KMT2AMEN1PPARGCYP2C19EDNRB | |
| SCHEMBL12890682 | 0.86 | KMT2A (0.40) | KMT2AMEN1PPARGEDNRBEED | |
| SCHEMBL832053 | 0.86 | PKM (0.44) | KMT2AMEN1PPARGEEDSUZ12 | |
| SCHEMBL12890680 | 0.86 | KMT2A (0.41) | KMT2AMEN1PPARGEDNRBEED | |
| SCHEMBL829212 | 0.85 | GABRA1 (0.42) | KMT2AMEN1PPARGEEDSUZ12 | |
| SCHEMBL832056 | 0.83 | KMT2A (0.41) | KMT2AMEN1PPARGEEDSUZ12 | |
| SCHEMBL832411 | 0.82 | EDNRB (0.49) | PPARGEDNRBMAPT | |
| SCHEMBL832829 | 0.82 | KMT2A (0.38) | KMT2AMEN1PPARGEEDSUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | IDO1, IDO2, ZC3HAV1 | KMT2A 1322/4885MEN1 1177/4885PPARG 3860/4885 |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | KMT2A 321/4885MEN1 2084/4885PPARG 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.